ANGPTL Inhibitor

Evinacumab (REGN1500) is a human anti-ANGPTL3 (angiopoietin-like protein 3) monoclonal antibody (IgG4 class antibody). Evinacumab reduces plasma lipids in dyslipidemic mice by blocking ANGPTL3. Evinacumab can be used in studies of homozygous familial hypercholesterolaemia (HoFH), refractory hypercholesterolaemia (both familial and non-familial) and severe hypertriglyceridaemia.

Vupanorsen (sodium) is an N-acetyl galactosamine-conjugated antisense oligonucleotide that inhibits Angiopoietin-like 3 (ANGPTL3) protein synthesis. Vupanorsen (sodium) lowers triglycerides and atherogenic lipoproteins.

Anti-ANGPTL4 Antibody is a CHO expressed human antibody targeting ANGPTL4. Anti-ANGPTL4 Antibody has a huIgG1-type heavy chain and a huλ-type light chain with a predicted molecular weight (MW) of 150 kDa. An isotype control for Anti-ANGPTL4 Antibody can be found in Human IgG1 kappa, Isotype Control (HY-P99001).

Zodasiran is a siRNA targeted to ANGPTL3 in the liver.

Corveldebart is a monoclonal antibody of immunoglobulin G1-kappa that targets ANGPTL4. Corveldebart can be used as an immunomodulator.

Lexosiran is a siRNA that inhibits ANGPTL3 (angiopoietin-related protein 3) synthesis, and can be use for the study of antihyperlipidaemic.

Zodasiran sodium scrambled negative control is the sequence scrambled negative control of Zodasiran sodium.

DC371739 is a potent and orally activity PCSK9 inhibitor. DC371739 decreases the mRNA expression of PCSK9 and ANGPTL3. DC371739 decreases the protein expression of PCSK9 and increases the protein expression of LDLR. DC371739 has the potential for the research of hyperlipidemia.

Vupanorsen is an N-acetyl galactosamine-conjugated antisense oligonucleotide that inhibits Angiopoietin-like 3 (ANGPTL3) protein synthesis. Vupanorsen lowers triglycerides and atherogenic lipoproteins.

Zodasiran sodium is a siRNA targeted to ANGPTL3 in the liver.

Solbinsiran sodium is a siRNA targeted to hepatic ANGPTL3.

Solbinsiran sodium scrambled negative control is the sequence scrambled negative control of Solbinsiran sodium.

Lexosiran sodium is a siRNA that inhibits ANGPTL3 angiopoietin-related protein 3 synthesis, and can be use for the study of antihyperlipidaemic.

Solbinsiran is a siRNA targeted to hepatic ANGPTL3.

Vupanorsen sodium scrambled negative control is the sequence scrambled negative control of Vupanorsen sodium.

Anti-ANGPTL8 Antibody is a CHO expressed human antibody targeting ANGPTL8. Anti-ANGPTL8 Antibody has a huIgG1-type heavy chain and a huκ-type light chain with a predicted molecular weight (MW) of 150 kDa. An isotype control for Anti-ANGPTL8 Antibody can be found in Human IgG2 kappa, Isotype Control (HY-P99002).